Anchored in work originally undertaken at Massachusetts General Hospital, and Harvard Medical School, CytoSite Biopharma Inc. is developing a new technology to predict and monitor response to Immuno-Oncology therapy. The company is developing a novel and proprietary small molecule PET imaging probe designed to enable clinicians to predict early in the treatment cycle which patients will respond to immuno-oncology therapy. The firm's products detect active Granzyme B, the primary element responsible for the killing of tumor cells by the immune system - enabling individually-optimized treatments for patients, and more rapid evaluation of new drugs and drug combinations, using non-invasive, whole-body PET imaging.
